Drug Profile

RAD 101

Alternative Names: 18F-RAD101; F18; RAD-101

Latest Information Update: 17 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Radiopharm Theranostics
Developer Imperial College of Science, Technology and Medicine; Radiopharm Theranostics
Class Diagnostic agents; Fluorine radioisotopes; Radiopharmaceutical diagnostics; Small molecules
Mechanism of Action Radionuclide imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

17 Jun 2025 RAD 101 receives Fast Track designation for Brain metastases [IV] (Diagnosis, Recurrent) in USA
13 Dec 2024 Phase-II clinical trials in Brain metastases (Diagnosis, Recurrent) in USA (IV) (NCT06777433)
24 Jun 2022 Phase-II clinical trials in Glioma (Diagnosis) in United Kingdom (IV), prior to June 2022 (Radiopharm Theranostics pipeline June 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com